BAXTER INTERNATIONAL INC
BAXAPI behind this page
BAX FY 2025 request
Playground key active
/api/financials?ticker=BAX&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 11,244 | 10,636 | +5.7% |
Show Product Lines breakouts |
|||
| Advanced Surgery · Medical Products & Therapies | 648 | 603 | +7.5% |
| Advanced Surgery · Medical Products & Therapies | 550 | 501 | +9.8% |
| Advanced Surgery · Medical Products & Therapies | 1,198 | 1,104 | +8.5% |
| Care & Connectivity Solutions · Healthcare Systems & Technologies | 1,372 | 1,311 | +4.7% |
| Care & Connectivity Solutions · Healthcare Systems & Technologies | 539 | 503 | +7.2% |
| Care & Connectivity Solutions · Healthcare Systems & Technologies | 1,911 | 1,814 | +5.3% |
| Drug Compounding · Pharmaceuticals | 1,141 | 1,038 | +9.9% |
| Drug Compounding · Pharmaceuticals | 1,141 | 1,038 | +9.9% |
| Front Line Care · Healthcare Systems & Technologies | 871 | 843 | +3.3% |
| Front Line Care · Healthcare Systems & Technologies | 289 | 294 | -1.7% |
| Front Line Care · Healthcare Systems & Technologies | 1,160 | 1,137 | +2.0% |
| Infusion Therapies & Technologies · Medical Products & Therapies | 2,236 | 2,279 | -1.9% |
| Infusion Therapies & Technologies · Medical Products & Therapies | 1,865 | 1,824 | +2.2% |
| Infusion Therapies & Technologies · Medical Products & Therapies | 4,101 | 4,103 | -0.0% |
| Injectables & Anesthesia · Pharmaceuticals | 749 | 780 | -4.0% |
| Injectables & Anesthesia · Pharmaceuticals | 603 | 593 | +1.7% |
| Injectables & Anesthesia · Pharmaceuticals | 1,352 | 1,373 | -1.5% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Non Us | 828 | 797 | +3.9% |
| Healthcare Systems & Technologies · Operating Segments | 3,071 | 2,951 | +4.1% |
| Healthcare Systems & Technologies · US | 2,243 | 2,154 | +4.1% |
| Medical Products & Therapies · Non Us | 2,415 | 2,325 | +3.9% |
| Medical Products & Therapies · Operating Segments | 5,299 | 5,207 | +1.8% |
| Medical Products & Therapies · US | 2,884 | 2,882 | +0.1% |
| Pharmaceuticals · Non Us | 1,744 | 1,631 | +6.9% |
| Pharmaceuticals · Operating Segments | 2,493 | 2,411 | +3.4% |
| Pharmaceuticals · US | 749 | 780 | -4.0% |
Show Geography breakouts |
|||
| Emerging markets | 1,394 | 1,350 | +3.3% |
| Non Us | 5,122 | 4,786 | +7.0% |
| Non Us · Corporate Non Segment | 135 | 33 | +309.1% |
| Rest of world | 3,728 | 3,436 | +8.5% |
| US | 6,122 | 5,850 | +4.6% |
| US · Corporate Non Segment | 246 | 34 | +623.5% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 381 | 67 | +468.7% |
| Cost of Revenue | 7,865 | 6,652 | +18.2% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 1,603 | 1,464 | +9.5% |
| Medical Products & Therapies · Operating Segments | 3,065 | 2,867 | +6.9% |
| Pharmaceuticals · Operating Segments | 1,777 | 1,612 | +10.2% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Foreign Exchange Contract | -6 | -8 | +25.0% |
| Gross Profit | 3,379 | 3,984 | -15.2% |
| Selling, General & Administrative | 2,890 | 2,967 | -2.6% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 873 | 836 | +4.4% |
| Medical Products & Therapies · Operating Segments | 1,162 | 1,176 | -1.2% |
| Pharmaceuticals · Operating Segments | 429 | 396 | +8.3% |
| Research & Development | 518 | 590 | -12.2% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 190 | 184 | +3.3% |
| Medical Products & Therapies · Operating Segments | 209 | 216 | -3.2% |
| Pharmaceuticals · Operating Segments | 101 | 91 | +11.0% |
| Goodwill Impairment Loss | 485 | 425 | +14.1% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 485 | 425 | +14.1% |
| Reportable Segment · Material Reconciling Items | -485 | -425 | -14.1% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 485 | 425 | +14.1% |
| Other Operating Income Expense Net | -206 | -12 | -1616.7% |
| Operating Income | -308 | 14 | -2300.0% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 441 | 468 | -5.8% |
| Medical Products & Therapies · Operating Segments | 970 | 950 | +2.1% |
| Pharmaceuticals · Operating Segments | 222 | 313 | -29.1% |
| Reportable Segment | -308 | 14 | -2300.0% |
| Reportable Segment · Operating Segments | 1,633 | 1,731 | -5.7% |
Show Disposal Group Classification breakouts |
|||
| Discontinued Operations Disposed Of By Sale | -6 | -112 | +94.6% |
| Discontinued Operations Disposed Of By Sale · Kidney Care | -6 | -112 | +94.6% |
| Interest Income Expense Nonoperating Net | 238 | 341 | -30.2% |
Show Business Segments breakouts |
|||
| Reportable Segment | 238 | 341 | -30.2% |
Show Disposal Group Classification breakouts |
|||
| Discontinued Operations Disposed Of By Sale | 13 | 13 | 0.0% |
| Discontinued Operations Disposed Of By Sale · Kidney Care | 13 | 13 | 0.0% |
| Other Non-Operating Income (Expense) | -41 | -38 | -7.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | -41 | -38 | -7.9% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -11 | -6 | -83.3% |
Show Disposal Group Classification breakouts |
|||
| Discontinued Operations Disposed Of By Sale | 7 | 10 | -30.0% |
| Discontinued Operations Disposed Of By Sale · Kidney Care | 7 | 10 | -30.0% |
| Income Before Taxes | -505 | -289 | -74.7% |
Show Business Segments breakouts |
|||
| Reportable Segment | -505 | -289 | -74.7% |
| Income Tax Expense (Benefit) | 395 | 37 | +967.6% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | 2 | 2 | 0.0% |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | -900 | -326 | -176.1% |
| Income Loss From Discontinued Operations Net Of Tax | -57 | -312 | +81.7% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Kidney Care | 14 | — | — |
| Accumulated Translation Adjustment · Kidney Care | -126 | — | — |
Show Disposal Group Classification breakouts |
|||
| Discontinued Operations Disposed Of By Sale | -57 | -312 | +81.7% |
| Discontinued Operations Disposed Of By Sale · Kidney Care | -57 | -312 | +81.7% |
| Net Income | -957 | -638 | -50.0% |
Show Equity Components breakouts |
|||
| Parent | -957 | -649 | -47.5% |
| Retained Earnings | -957 | -649 | -47.5% |
| Net Income | -957 | -649 | -47.5% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | 20 | 4 | +400.0% |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -126 | — | — |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -106 | 2 | -5400.0% |
| Income Loss From Continuing Operations Per Basic Share | -1.75 | -0.64 | -173.4% |
| Income Loss From Continuing Operations Per Diluted Share | -1.75 | -0.64 | -173.4% |
| Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share | -0.12 | -0.63 | +81.0% |
| Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share | -0.12 | -0.63 | +81.0% |
| EPS (Basic) | -1.87 | -1.27 | -47.2% |
| EPS (Diluted) | -1.87 | -1.27 | -47.2% |
| Wtd Avg Shares (Basic) | 513 | 510 | +0.6% |
| Wtd Avg Shares (Diluted) | 513 | 510 | +0.6% |
| Interest Income | -52 | -67 | +22.4% |
| Comprehensive Income | -701 | -1,105 | +36.6% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (FY) | — | — | — |
Show Statement Operating Activities Segment breakouts |
|||
| Segment Continuing Operations | -2 | 10 | -120.0% |
| Operating Lease Lease Income | 350 | 380 | -7.9% |
| Other Expenses (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | -36 | -1 | -3500.0% |
| Medical Products & Therapies · Operating Segments | -107 | -2 | -5250.0% |
| Pharmaceuticals · Operating Segments | -36 | -1 | -3500.0% |
| Interest Expense | 290 | 408 | -28.9% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,966 | 1,764 | +11.5% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 | 1.97 | 1.76 | +11.9% |
| Accounts Receivable | 1,861 | 1,679 | +10.8% |
| Inventory | 2,232 | 2,046 | +9.1% |
| Prepaid Expenses & Other Current Assets | 813 | 753 | +8.0% |
| Total Current Assets | 6,872 | 8,853 | -22.4% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,910 | 2,870 | +1.4% |
| Goodwill | 4,929 | 5,275 | -6.6% |
Show Product Lines breakouts |
|||
| Front Line Care · Healthcare Systems & Technologies | 1.52 | 1.99 | -23.6% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 3,087 | 3,550 | -13.0% |
| Medical Products & Therapies · Operating Segments | 1,265 | 1,185 | +6.8% |
| Pharmaceuticals · Operating Segments | 577 | 540 | +6.9% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 4,929 | 5,275 | -6.6% |
| Operating Lease Right-of-Use Assets | 276 | 306 | -9.8% |
| Other Non-Current Assets | 699 | 755 | -7.4% |
| Total Assets | 20,055 | 25,782 | -22.2% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 2,298 | 2,509 | -8.4% |
| Developed technology, including patents | 774 | 1,056 | -26.7% |
| Other Intangible Assets | 19 | 20 | -5.0% |
| Trade Names | 781 | 851 | -8.2% |
| Deferred Tax Assets | 200 | 204 | -2.0% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 4,369 | 5,223 | -16.4% |
| Current Liabilities | |||
| Short Term Borrowings | 1 | 2,126 | -100.0% |
| Long Term Debt And Capital Lease Obligations Current | 2 | 626 | -99.7% |
| Accounts Payable | 999 | 968 | +3.2% |
| Accrued Liabilities | 1,968 | 1,861 | +5.7% |
| Total Current Liabilities | 2,970 | 6,511 | -54.4% |
| Deferred Revenue (Current) | 141 | 131 | +7.6% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 223 | 243 | -8.2% |
| Other Non-Current Liabilities | 1,287 | 1,076 | +19.6% |
| Total Liabilities | 13,953 | 18,758 | -25.6% |
| Long-Term Debt | 9,438 | — | — |
| Long-Term Debt (Q) | — | — | — |
Show Measurement Input Type breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 9,436 | 10,374 | -9.0% |
| Estimate Of Fair Value Fair Value Disclosure | 8,714 | 9,295 | -6.3% |
| Deferred Tax Liabilities | 245 | 103 | +137.9% |
| Contract With Customer Liability Noncurrent | 36 | 40 | -10.0% |
| Other Liabilities | |||
| Long Term Debt And Lease Obligation Excluding Current Maturities | 9,473 | 10,374 | -8.7% |
| Stockholders' Equity | |||
| Common Stock | 683 | 683 | 0.0% |
| Treasury Stock Common Value | -10,873 | -11,059 | +1.7% |
| Additional Paid In Capital Common Stock | 6,368 | 6,421 | -0.8% |
| Retained Earnings | 13,705 | 14,929 | -8.2% |
| Accumulated Other Comprehensive Income | -3,754 | -4,010 | +6.4% |
Show Statement Operating Activities Segment breakouts |
|||
| Segment Continuing Operations | -110 | -108 | -1.9% |
| Total Stockholders' Equity | 6,129 | 6,964 | -12.0% |
| Minority Interest | -27 | 60 | -145.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 6,102 | 7,024 | -13.1% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -514 | -475 | -8.2% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -110 | -108 | -1.9% |
| Accumulated Net Unrealized Investment Gain Loss | 3 | 3 | 0.0% |
| Accumulated Other Comprehensive Income | -3,754 | -4,010 | +6.4% |
| Accumulated Translation Adjustment | -3,133 | -3,430 | +8.7% |
| Additional Paid In Capital | 6,368 | 6,421 | -0.8% |
| Common Stock | 683 | 683 | 0.0% |
| Noncontrolling Interest | -27 | 60 | -145.0% |
| Parent | 6,129 | 6,964 | -12.0% |
| Retained Earnings | 13,705 | 14,929 | -8.2% |
| Treasury Stock Common | -10,873 | -11,059 | +1.7% |
| Total Liabilities & Equity | 20,055 | 25,782 | -22.2% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 981 | 997 | -1.6% |
| Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash | -32 | -28 | -14.3% |
| Deferred Income Taxes And Tax Credits | 77 | -262 | +129.4% |
| Stock-Based Compensation | 117 | 114 | +2.6% |
| Impairment Of Intangible Assets Indefinitelived Excluding Goodwill | 290 | 50 | +480.0% |
Show Business Segments breakouts |
|||
| Reportable Segment · Material Reconciling Items | -290 | -50 | -480.0% |
| Impairment Of Long Lived Assets To Be Disposed Of | 27 | 44 | -38.6% |
| Gains Losses On Extinguishment Of Debt | -16 | — | — |
| Other Non-Cash Items | 30 | 41 | -26.8% |
| Change in Accounts Receivable | -132 | -35 | -277.1% |
| Change in Inventory | -119 | -201 | +40.8% |
| Change in Prepaid & Other Assets | 72 | -125 | +157.6% |
| Change in Accounts Payable | 3 | 112 | -97.3% |
| Increase Decrease In Accrued Expenses And Other Current Liabilities | 149 | 44 | +238.6% |
| Other Operating Activities Cash Flow Statement | -81 | -31 | -161.3% |
| Net Cash Provided By Used In Operating Activities Continuing Operations | 951 | 819 | +16.1% |
| Cash Provided By Used In Operating Activities Discontinued Operations | -106 | 200 | -153.0% |
| Net Cash from Operations | 845 | 1,019 | -17.1% |
| Deferred Income Taxes | 77 | -262 | +129.4% |
| Investing Activities | |||
| Payments To Acquire Productive Assets | -513 | -446 | -15.0% |
| Payments To Acquire Businesses Net Of Cash Acquired | -9 | -14 | +35.7% |
| Other Investing Activities | 58 | 16 | +262.5% |
| Net Cash Provided By Used In Investing Activities Continuing Operations | -464 | -410 | -13.2% |
| Cash Provided By Used In Investing Activities Discontinued Operations | 3,305 | -216 | +1630.1% |
| Net Cash from Investing | 2,841 | -626 | +553.8% |
| Financing Activities | |||
| Proceeds From Issuance Of Long Term Debt | 1,998 | — | — |
| Debt Repayments | -5,489 | -2,657 | -106.6% |
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | -300 | 296 | -201.4% |
| Payments Of Dividends Common Stock | -348 | -590 | +41.0% |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 30 | 71 | -57.7% |
| Payment For Contingent Consideration Liability Financing Activities | -50 | — | — |
| Proceeds From Payments For Other Financing Activities | -57 | -31 | -83.9% |
| Net Cash from Financing | -4,216 | -1,081 | -290.0% |
| Supplemental | |||
| Income Taxes Paid | 222 | — | — |
| Interest Paid | 303 | 401 | -24.4% |
| Unpaid Capital Expenditures (FY) | — | — | — |
Show Property Plant And Equipment By Type breakouts |
|||
| Property Plant And Equipment | 74 | 64 | +15.6% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations | 84 | -96 | +187.5% |
| Net Change in Cash | -446 | -784 | +43.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 1,968 | 2,414 | -18.5% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,968 | 1,766 | +11.4% |
Values in millions USD. Source: SEC EDGAR 10-K filing.